NEW YORK, (GenomeWeb News) - Cell Signaling Technology said today it has agreed to extend an agreement with AstraZeneca, under which the drugmaker will continue to use its technology to identify biomarkers for targeted compounds.
This is the fourth such agreement (https://www.genomeweb.com/issues/news/133229-1.html ) between the companies. CST said it will continue using its PhosphoScan technology to provide AstraZeneca with phosphorylation profiles of target kinases for an antibody development program that the companies are performing together under a parallel agreement.
CST Director of Business Development Christopher Bunker said the Danville, Mass.-based company will translate information it finds using the PhosphoScan into biomarker assays for AstraZeneca.
Financial terms of the agreement were not released.